header logo image


Page 790«..1020..789790791792..800810..»

Everything You Should Know About Night Blindness – Auto World News

December 15th, 2019 9:54 pm

Driving at night can be risky, whether you have vision issues or not. When there is decreased visibility at night, it leaves you at a greater risk as a driver, and it also puts other drivers and pedestrians at an increased risk of injury.

Around 72% of pedestrian accidents resulting in serious injuries happen at night, and 78% of those occur in urban areas.

When you're driving at night it's more challenging to react to other drivers, to see obstacles in the roadway, and to judge distances. Visibility is only around 500 feet when you're using your high beams, and that goes down to around 250 feet when you're using your normal headlights.

It's tough on your eyes to adjust how they function when you're frequently switching between bright headlights and dark roadways, and for some people with night blindness, this can all be even more challenging.

Sometimes you might hear people joking about being "blind" when they drive at night, but there are real medical conditions that can make it difficult to see at night. Nyctalopia is the name for night blindness.

With nyctalopia, someone has a hard time seeing in darkness or dim light.

It can take their eyes an unusually long time to adjust when they go from light to dark, and the problem stems primarily from an issue with the rod cells of the retina. The rod cells are responsible for taking light rays and converting them into electrical signals, which your brain then interprets as images.

When your rod cells become damaged, then that can lead to night blindness.

Night blindness isn't in and of itself a condition but is instead a symptom of something else.

Some of the reasons your rods might be damaged that can lead to night blindness include:

Night blindness does impact a person's ability to see at night and in dim or dark light, but they aren't completely blind.

Some of the symptoms of night blindness include:

Other seemingly non-related symptoms may occur when you have night blindness such as headaches, nausea, vomiting, and blurry or cloudy vision.

What about seeing halos around lights? A lot of people deal with this when they're driving at night, but it doesn't necessarily mean you have night blindness.

Halos mean that you see rings or bright circles around a source of light. When you're driving, this might mean a headlight or a streetlight.

Sometimes it's normal to see halos, but halos can also be caused by cataracts, LASIK surgery, or wearing glasses or contact lenses.

If you suddenly experience halos or they occur along with symptoms like blurry vision or pain, then it could indicate that you have a serious eye disorder, and you need to speak with your doctor. The causes of halos are different than the causes of night blindness.

Halos occur when there's a bend in the light that enters your eyes.

Treatments for halos depend on the cause. For example, if halos are due to cataracts, then the problem may be eliminated when you get cataract surgery. Similarly, if it's from glaucoma, laser surgery might help with the problem.

If you think you could have night blindness, the first thing to do is speak with your eye doctor.

Treating the condition, similarly to treating halos, requires that you have a diagnosis of the underlying condition, and then treatment is guided toward remedying that.

For example, if your night blindness comes from cataracts, you can have surgery. During cataract surgery, your cloudy lens on your eye is replaced with a clear artificial lens. Then, you should find that your night blindness is significantly improved.

If your night blindness comes from a deficiency of vitamin A, then your doctor may recommend supplementation.

Some of the genetic conditions leading to night blindness aren't treatable, and if this is the case, then the recommendation may be that you don't drive at night.

Even if you don't technically have night blindness, it's generally more challenging to drive at night than during the day.

Tips for safe nighttime driving include:

If you feel like your nighttime driving is impaired in any way, it's best to avoid driving. Speak with an eye doctor and figure out what needs to be done, but if at all possible, don't risk it by heading out on the roadways.

The winter is an especially risky time because you spend more time driving when it's dark, and it can affect depth perception, peripheral vision, and color recognition.

Read the original:
Everything You Should Know About Night Blindness - Auto World News

Read More...

2020.. the year when corporate actions finally have to match up to our words – Insider.co.uk

December 15th, 2019 9:54 pm

We are only as blind as we want to be is a quote credited to civil rights activist and poet Maya Angelou.

It acts as a stark reminder to many of us of how accountable we are for our actions as people, as well as a warning to businesses not to take the status quo for granted.

Recent times have been characterised by change: fluctuating politics; shifts in consumer habits; growing momentum behind purpose in business. Every business is now alive to the realities of change, and the urgency of aligning profits with purpose.

Next year is the starting gun for the single most important decade of the Post-War era: the decade of cleantech, of environmental preservation, of hope but also of crisis. The blindness Angelou refers to is what threatens all of us. Soon, corporate myopia will be viewed as a wilful choice rather than happenstance.

Next year will be the first time we will be held accountable for how we have embraced change. Are we modifying our behaviour to reduce climate emissions? Have we reduced our waste? The arrival of COP26 in Glasgow will certainly sharpen our senses to these questions.

Whats more, the scrutiny extends well beyond the environment. There are other urgencies. Are we tackling discrimination? Do we do enough to protect vulnerable or minority communities? What about encouraging STEM careers or supporting the next generation of leaders? How are we closing the gender pay gap or supporting the LGBTQ+ community?

These questions are reasonable expectations of businesses, and business leaders. The collective and the individual are not as separate as one might imagine, which should act as a warning signal to anyone at the top of an organisation.

The year 2020 is the year that these questions will become entrenched in the everyday. Cause will have consequence: consumers will vote with their wallets; suppliers will win and lose contracts based on how accountable they prove themselves to be; commercial buyers will ask for more; and shareholders and boards will double-down on governance.

Never before has strategic communications become so intertwined with action even activism, in some senses. Reputation is defined as the beliefs or opinions that are generally held about someone or something, and those beliefs and opinions will be defined by much more than words.

The choices we make now might help to define how well your reputation holds together in the coming years. Considerations include:

As the year draws to a close, businesses should prepare for a change of pace in 2020. Now is the time to ask whether your reputation will stand up to what is coming. As Maya Angelou said, we are only as blind to change as we want to be.

Read the original here:
2020.. the year when corporate actions finally have to match up to our words - Insider.co.uk

Read More...

FG halts River blindness in 3 states – Daily Trust

December 15th, 2019 9:54 pm

The transmission of Onchocerciasis also known as River Blindness has been halted in Plateau, Nasarawa and Kaduna states.

National Coordinator, Neglected Tropical Diseases (NTDs) of the Federal Ministry of Health, Dr Chukwuma Anyaike made the disclosure yesterday during the National Onchocerciasis Elimination Committee (NOEC) meeting in Abuja.

Onchocerciasis is a parasitic disease caused by small worms living in the body. It is transmitted by the bite of the black fly, the vector for River blindness. Symptoms of the disease include severe itching, hanging groin, thick and rough skin and blindness.

Dr Anyaike said Nigeria had a significant burden of the disease with presence in 32 states and the Federal Capital Territory (FCT).

Professor Betrand Nwoke, chairman of the committee said the meeting was organised to honour those who have contributed in ending the transmission of the disease in the three states.

He said experts have been working towards the elimination of the disease in the last 20 years, adding that results from Kebbi, Zamfara, Oyo and Bauchi states showed that the disease was at the verge of interruption in those states.

He said interruption of the disease in the three states meant that six million Nigerians would no longer be given mectizan for treatment.

He said the achievement was possible through collaborative efforts of the Federal Ministry of Health, international partners like Carter Centre, Sigth Savers, UNICEF and state governments and individuals.

Related

Read this article:
FG halts River blindness in 3 states - Daily Trust

Read More...

How a Blind Man Mastered this Impossible Violin Piece – RADII

December 15th, 2019 9:54 pm

27-year-old Zhang Zheyuan is prolific. As a violinist, hes toured with elite performance troupes, traveled the world, and played in Olympic ceremonies. And hes done it all in darkness.

Zheyuan was born with congenital blindness in southwest Chinas Yunnan province. He attended a special school for the disabled, learning side by side with other blind children, in a program designed to equip them with the kind of barebones skills theyd need to survive and make a living, if they were to eventually emerge on their own into the world. And that is an if theres a tacit understanding that many of the programs students will never achieve true independence.

For Chinas blind, the default path is massage. Some age-old idea posits that, sans vision, ones sense of touch becomes hyper-developed, allowing blind masseurs to navigate through tensions and knots in the muscles like some kind of bootleg therapeutic Daredevil (having experienced a blind massage, I feel a twang of harsh honesty to recall that it was generally unremarkable). Its unclear whether the tradition remains alive primarily out of a genuine belief in its tenets, or out of a public willingness to accept it as a sort of de facto, self-sustaining social support system.

Around the time when other children were setting off down the one-way road of massage education, Zheyuan was studying violin. As a productive hobby, of course, not a future career.

One evening while practicing at his instructors home, he recalls, rain began to fall heavily outside. The instructor invited Zheyuan to stay for dinner until the storm cleared, putting a Bach record onto the turntable. Zheyuan ate, awash in the white noise of vinyl crackle and raindrops on windows, taking in the sounds of Bachs compositions. Its worth noting that Bach too endured much hardship in his life, becoming orphaned at age 10 and eventually going blind himself, dying as the result of a botched surgery.

Zheyuan listened to his teacher, of whom Bach was a personal favorite, as he relayed these stories over Art of Fugue. He recounts feeling deeply affected by Bachs ability to transform his trauma and suffering into something beautiful that could move others. When the rain cleared he left with a head full of new ideas.

When Zheyuan told his school, no, I dont want to study massage, Id actually like to play the violin, he was met with harsh rebuke. Why would someone like Zheyuan want to throw himself into a useless pursuit like that? Why would he want to shuck off the dehumanizing-in-a-way-I-cant-quite-put-my-finger-on, but also safe and reliable tradition of becoming a masseur? Did he want to starve?

Zheyuan left the school that same year.

Amidst a firestorm of dream-shattering good intentions, Zheyuans father was a pillar of support. When others told him to be realistic, it was his father who read Zheyuans sheet music aloud, and told him to do something he loved. Zheyuan, with his fathers help, woke up routinely at 7:00 AM and practiced for ten hours each day.

Its touching, but realistically, it should have been insufficient. When your friends, family, teachers, and caretakers are all telling you that your dream is not of the come true variety, but of the pipe variety, and when that assessment is bolstered and supported by an unfair and undeserved truth, namely that you are different than others, and less capable than others, and unable to do the basic things that others take for granted (others, they might add, who have failed to achieve the very same dream youve identified), the support of one person, sadly, should not be enough to align your inner compass. Its in this understanding that we move closer to the true nature of Zheyuans greatness.

Lets condense the remainder of Zheyuans blow-by-blow history. He called up the China Disabled Persons Performing Arts Troupe and played his violin on the phone. He was invited to join the elite troupe, and spent the next two years touring the world. He played at the Lincoln Center, placed in a national TV competition, and captivated audiences with a solo performance at the Asia Paralympic Games.

After two years though, uncertainty started to creep in. Zheyuan was undeniably good for a blind man the best in the world. But Zheyuan wanted to be more than that.

Much to the dismay of his family and friends, who felt that against all odds, he had already achieved his fantastic impossible goal, he went back to school.

The Central Conservatory of Music in Beijing told him they would love to accept him, but unfortunately, didnt have the facilities required to educate blind students. Zheyuan only heard the first part of that sentence, renting out a small basement near the university and auditing all the classes there.

American schools were stunned by his playing, but turned him away for his poor English. Zheyuan started studying, memorizing a comprehensive English textbook word for word using the text-reading app on his phone, it was the only method available to him. Clearly, this is a man who doesnt give a damn if you think hes already reached his zenith. He has further zeniths in mind, and who are you to tell him otherwise? You probably dont even play the violin.

That was six years ago. The day that we wrapped on shooting this documentary film, September 20th, 2019, Zheyuan set off on the next leg of his march down an unending and personally-bricked road: a scholarship at the University of Sheffield in England. Goodness knows where hell go next.

When it comes to being blind, we tend to feel like its quite self-explanatory. The absence of vision. Wouldnt that be something?

In five days of intensive, 9-to-5 shoots with Zheyuan, we learned that blindness is far more complex, and far less one dimensional than that. Its not the absence of vision, full stop. Its the absence of vision as it relates to ones physical safety, and the absence of vision as it relates to ones social life, relates to ones relationships, relates to ones concept of self. Blindness is not a singular and major affliction that blankets Zheyuans life, but a complex and ever-moving truth that changes every aspect of his lived experience, in ways big, small, and diverse.

Shooting one of our RADII Voices films requires a significant commitment from the subject, and most of the time theyre not very familiar with the filmmaking process. Zheyuan, more than anyone, displayed an immeasurable readiness and tolerance for the (often grueling) demands of the shoot.

When the crew was collapsing onto park benches, shoulders sagging with fatigue, Zheyuan was ready for the next shot. When we were scrambling madly to reach our location while the light was perfect, Zheyuan was at the front of the mob. Not once did he question anything or betray a hint of frustration. He was here to make a film, and he brought to that task the same steely resolve he brings with him everywhere.

Interestingly, from the outset, Zheyuan was preoccupied with the visual nature of our project. He wanted to know the shooting style and the visual motifs we had in mind. We sent him references, which he poured over with the help of his dad. When we created a flier for our live music event in Shanghai (Zheyuan improvising with experimental electronic musician Laughing Ears), he sent us back revisions to improve our graphic design.

Zheyuan moves around with a kind of deftness. He bumps into something every now and again, but has an uncanny ability to catch himself that could only come from a lifetime of practice (its worth noting that we worked as a team exclusively in environments that were unfamiliar to him). Somewhere like his home or his school, his disability could very well go unnoticed. He can navigate through rooms based on a totally alternate set of sensory skills he can tell if the walls are metal, and at which point they change to wood, based on the reverberations of spoken voices in the room. Once hes been in a place for a few minutes, hes already drawn up a memory map of each object and corner.

That kind of alternate sensory skill extends to his specially-designed smartphone, which uses a computer narrator to orate texts, emails, web browsing, etc. It does so at approximately 300 million words per minute, sentences and whole paragraphs whizzing by in a wild gaussian blur. The Mandarin was unintelligible to our Chinese crew members, and when he switched the device to English, I too was stumped. Zheyuan found it amusing English was his second language, after all, and here he was scoring higher than me on listening comprehension. He had trained to do this.

In between shots, wed return periodically to Zheyuans hotel room for meals or power naps. The hotel was a nice one, with wall-to-wall windows and plenty of natural light. Good feng shui. The only thing that stood out was that some birdbrained interior designer had taken it upon themselves to construct the bathrooms doors and walls out of perfectly clear glass. Using the restroom, there was an unspoken rule that all would avert their eyes from the glass cube of public shame.

It wasnt until the fourth day, when we returned to the room with a full crew of additional day-rate cameramen, that one of them cracked a joke about the rooms obvious design flaw.

Zheyuan turned and asked me in English, The bathroom is made of glass?

I told him it was. He laughed it off and said something about how silly it was. But I knew that he was having to come to terms, in one instant, with the sudden realization of public awkwardness wed been enduring all week. Blindness is more than a physical inconvenience its an exclusion from a communal experience that is enjoyed ungratefully by nearly all living creatures.

When wed wrapped the last scene on day five, we felt that euphoric sense of bliss and relief that comes with crossing any finish line. Zheyuan was beaming. We went straight to a bar to celebrate with beer and chicken wings.

Zheyuan is able to sense the social cues of conversation based on things like the tightened roundness of words spoken with a smile, or the direction someone is facing when telling a story, and the resulting way their voice projects through space. He knows when youre trying to shake his hand, or when you want to help him with his bags. Sharing a communal basket of chicken wings in the center of the table can be a little tricky, but is overall very manageable.

At one point, I asked him if he could sign the vinyl record wed used in the film, as a memento of our time together.

Sign it? he said. I can only sign it in braille!

Id put my foot in my mouth. Even the simple pleasure of autographing something for a fan (which by now, I had become), writing ones own name, was outside of Zheyuans experience.

But when hed said that, hed done it with a sincere smile, laughing about it. This is classic Zheyuan.

The amazing thing about Zheyuan is not that he has mastered the violin. The amazing thing about Zheyuan is that, saddled with a challenge more immense than most people have ever known, he holds himself like someone who is completely unbothered in every moment. More than unbothered, but grateful.

Through one week of intense shooting, outside of his element, being prodded and shuttled around a foreign city by a crew of near-strangers, Zheyuan complained zero times. The only thing he brought forward was productive energy and assurance, even at times when we had little of our own. When he ran out of that, he slept.

It occurred to me that it was this attunement to a greater understanding, and a certainty about ones place in this world, that allows Zheyuan to do what he does. In spite of his challenges, Zheyuan has mastered his outlook on life, and he has mastered himself, in an almost nirvanic, Buddhist kind of way.

Zheyuan is not amazing because he has mastered the violin. He is amazing because he has mastered Zheyuan. His music is an expression of that a symptom of the greater illness of freedom and conviction in ones own inner truth. We hope you enjoy Zheyuans story as much as we enjoyed telling it with him.

More:
How a Blind Man Mastered this Impossible Violin Piece - RADII

Read More...

Biochemistry and Molecular Biology Degree Fully Accredited by ASBMB – UMass News and Media Relations

December 15th, 2019 9:53 pm

The American Society for Biochemistry and Molecular Biology (ASBMB) recently awarded full accreditation to the UMass Amherst biochemistry and molecular biology B.S. degree.

Aspects of the departments application that were considered particularly noteworthy according to the society include excellent faculty, outstanding in both teaching and research, integration of programs that promote student teamwork and communication skills, career advising and the advanced course-based undergraduate research experience (CURE) allowing students to gain authentic research experiences.

Jennifer Normanly, head of the department, says, Students who graduate from an ASBMB-accredited program have the opportunity to take an assessment, an exam, to have their degree certified by ASBMB, showing prospective graduate schools and potential employers that the students have met the societys high academic standards.

Dean Tricia Serio of the College of Natural Sciences said of the accomplishment, I am thrilled to see this well-deserved recognition for our stellar undergraduate major in biochemistry and for the departments leadership in and dedication to preparing our students for successful careers in the life sciences.

ASBMB, based in Rockville, Maryland, was founded in 1906 to advance the science of biochemistry and molecular biology through publication of scientific and educational journals, the organization of scientific meetings, advocacy for funding of basic research and education, support of science education at all levels and by promoting the diversity of individuals entering the scientific workforce. It publishes three peer-reviewed research journals covering research in microbiology, molecular genetics, RNA-related research, proteomics, genomics, transcription, peptides, cell signaling, lipidomics and systems biology. The society has over 12,000 members and has awarded accreditation to 85 colleges/universities.

Continue reading here:
Biochemistry and Molecular Biology Degree Fully Accredited by ASBMB - UMass News and Media Relations

Read More...

Prof. recognized for her contributions to science – The Justice

December 15th, 2019 9:53 pm

Biology Department chair and Prof. Piali Sengupta (BIOL) was one of 443 recently elected Fellows of the American Association for the Advancement of Science in 2019.

On Nov. 26, the AAAS published a full list of all elected fellows, who come from different universities and study a broad range of subjects. The AAAS is the worlds largest general scientific society and is located in Washington, D.C.

The AAASs article explains that fellows represent the 24 fields, from social, economic and political sciences to the natural sciences, such as biological and medical sciences. Past notable fellows include inventor Thomas Edison in 1878, anthropologist Margaret Mead in 1934 and computer scientist Grace Hopper in 1963. Fellows are elected by their peers on the Council of AAAS, the governing body of the organization. AAAS began selecting fellows in 1874.

According to a Nov. 26 BrandeisNow article, the AAAS sent Sengupta an acceptance letter explaining why she received the honor. The letter said she was chosen for her distinguished contributions to the field of sensory neuroscience, particularly for defining the molecular genetics of chemical communication and thermosensation in C. elegans.

Sengupta runs a lab that is broadly grouped into two areas, according to her Brandeis staff biography. The first is looking at the model organism C. elegans to see its response attraction or aversion to stimuli, like changes in temperature and changes to the chemicals in its environment. Called the Axis of Taxis subgroup, they investigate the neuronal, molecular and circuit mechanisms by which this organism responds to the stimuli. This is the part of her research she was recognized for.

The second subgroup in the Sengupta lab looks in the cilia, the part of the neuron that has the signalling molecules to allow for chemical signal transduction. Those who work on this project are known as the Cilia Squad and investigate the morphological and functional properties of the sensory cilia by looking at their cellular and molecular mechanisms. The lab overall looks at the animals sensory experience through genetic, molecular and neuronal mechanisms to see how they respond to complex and changing environments. It is for these contributions that Sengupta was elected as an AAAS Fellow.

Sengupta said that she is honored to be elected as an AAAS fellow because of its mission of inclusivity. She told BrandeisNow, AAAS has a strong commitment to promoting science research, policy and education as well as to increasing diversity and inclusion in STEM fields. As a Fellow, I look forward to contributing to these missions.

As Sengupta said, the AAAS has a longstanding tradition of inclusivity. According to its website, AAAS is committed to ensuring that everyone has the opportunity to contribute to, and benefit from, science and engineering by encouraging the recruitment, development, and retention of scientists. The organization seeks to provide tools that expand access to STEM education, strengthen and diversify the science and technology workforce, and amplify underrepresented and marginalized voices within STEM.

The 443 electees will be honored with official certificates and blue and gold rosette pins, which symbolize science and engineering. The ceremony will take place on Feb. 15, 2020 in Seattle, WA.

Continued here:
Prof. recognized for her contributions to science - The Justice

Read More...

New Species of Bobtail Squid Discovered in Okinawa [Video] – SciTechDaily

December 15th, 2019 9:53 pm

By Okinawa Institute of Science and Technology (OIST) Graduate UniversityDecember 11, 2019

Cephalopods were the first intelligent animals on the planet.

This quote from Dr. Sydney Brenner, molecular geneticist and one of the founders of the Okinawa Institute of Science and Technology Graduate University (OIST), highlights the burgeoning scientific interest in cephalopods like cuttlefish, octopuses, and squid. These creatures are lauded for their complex nervous systems and intricate behavior but scientists still know relatively little about them.

Now, researchers in OISTs Molecular Genetics Unit, in collaboration with a researcher from Australia, have identified a new species of bobtail squid inhabiting Okinawas waters dubbed Euprymna Brenner in honor of the late Dr. Brenner, who passed away earlier this year. The scientists findings, published today (December 11, 2019) in Communications Biology highlight the rich biodiversity in the seas near Okinawa, and may shed light on the genes, behavior, and development of bobtail squid.

Our research strives to understand how these animals complicated brains work, said Gustavo Sanchez, lead author of the study. Were also compelled to explore why there is such a wide variety of species off the coast of Okinawa.

A video of Euprymna brenneri, a newly described species of bobtail squid.

Bobtails have unique features from true squid, including their rounded or bobbed posteriors, earning them the nickname dumpling squid. In fact, they are actually more closely related to cuttlefish. Bobtails can be raised in the laboratory, making them useful as model for studying cephalopod development, genetics, and behavior. Scientists have also observed advanced behaviors like associative learning and inherited personality and fitness traits in bobtails.

For the present study, the researchers scoured the Ryukyan archipelago for bobtails, searching in shallow waters. They found three different types of egg masses and two distinct adult bobtails.

This is a photo of Euprymna brenneri, taken by Jeff Jolly, a co-author of the study. Credit: Jeffrey Jolly, OIST

By studying the DNA and RNA expression, or transcriptomes, in 42 different individuals across 10 species, the researchers matched the adults with their corresponding egg types and identified one of them as Euprymna parva, which was previously miscategorized as a different genus. One egg mass lacked a corresponding adult; by DNA it appeared to be distantly related to a different species found in Australia and East Timor, Euprymna pardalota.

One Ryukyuan type of bobtail remained. In addition to sequencing its transcriptome, the scientists closely analyzed its morphology; Jeff Jolly observed distinctive patterns of suckers on its arms and tentacles. The researchers enlisted the help of systematist Dr. Amanda Reid, from the Australian Museum in Sydney, to carefully look over the species and formally describe them.

From their analyses, the scientists confirmed they had found a new species, which they named Euprymna brenneri. This species is the eleventh known in the Euprymna genus and will be useful in future phylogenetic and comparative studies, the researchers said.

Sydney Brenner was a mentor and a friend. It is an honor to name this new species after him as a small reminder of his importance in creating the field of molecular biology, and more broadly his efforts to foster the development of science in Okinawa, Singapore, and around the world, said Daniel Rokhsar, head of the Molecular Genetics Unit at OIST.

In addition to phylogeny, the scientists are interested in the bobtail squids symbiotic relationship with the Vibrio fischeri bacteria that populate a pouch-like organ on the squids underside. Bobtails conceal themselves under the sand throughout the day, then emerge at night to hunt. They use the bacteria, which glow, to help them camouflage and achieve more successful predation in the dark.

Theres a complicated choreography between the bacteria and squid, said Dr. Oleg Simakov, a co-author of the study. If we can understand this relationship, we think the bobtail could be a useful model organism for host-microbe interactions.

Moving forward, the researchers hope to discover more about the rich diversity of cephalopods off the shores of Okinawa, and to further explore the relationships between different bobtail species.

Reference: New bobtail squid (Sepiolidae: Sepiolinae) from the Ryukyu islands revealed by molecular and morphological analysis by Gustavo Sanchez, Jeffrey Jolly, Amanda Reid, Chikatoshi Sugimoto, Chika Azama, Ferdinand Marltaz, Oleg Simakov and Daniel S. Rokhsar, 11 December 2019, Communications Biology.DOI: 10.1038/s42003-019-0661-6

Follow this link:
New Species of Bobtail Squid Discovered in Okinawa [Video] - SciTechDaily

Read More...

EPA’s ‘transparency rule’ is bad for science and the environment – STAT

December 15th, 2019 9:53 pm

A proposed rule by the Environmental Protection Agency (EPA) that allegedly aims to strengthen transparency in regulatory science suggests that science is broken. It isnt.

We know it works because we can see the life-saving transplant technologies, hurricane forecasts, new medications, pest-resistant crops, and countless other breakthroughs that exist because of science. This discipline isnt perfect, but it is the best tool available to safeguard the planet and its people.

Last year, the EPA proposed a rule requiring that scientists disclose all raw data before any study conclusions would be considered. The rule, titled Strengthening Transparency in Regulatory Science, would apply retroactively to regulations already in place. It would make it harder to enact new regulations, because many studies from the past rely on personal medical information that was collected under confidentiality agreements and include consensus from reports that may not have shared all of the data according in ways compliant with the proposed rule.

advertisement

The EPA has received nearly 600,000 comments on the proposed rule.

The House Committee on Space, Science, and Technology recently held hearings on the transparency rule and, in a bipartisan show of support, advanced out of committee the Scientific Integrity Act. This legislation would require all federal agencies that conduct or use science to set up systems to address and better yet, prevent attacks on science, like the EPAs proposed rule. Please contact your representatives in Congress to support the Scientific Integrity Act.

Scientists like us have been raising our voices in opposition to a rule rooted in the misconception that science leaps to conclusions based on weak evidence in single papers. In reality, science works because it produces ideas that are continually tested under tremendous critical scrutiny over long periods of time.

We are writing not just for ourselves but on behalf of other leaders in open and reproducible science practices: Todd Vision, professor and founder of the Dryad Digital Repository; Laurie Goodman, editor-in-chief of the open-access journal GigaScience; Elizabeth Iorns, CEO of Science Exchange and the codirector of the Reproducibility Initiative; Carly Strasser, director of alliances and data strategy at the Fred Hutchinson Cancer Research Center; and Mark Johnston, editor-in-chief of the journal Genetics and former chair of the department of biochemistry and molecular genetics at the University of Colorado.

We are a group of scientists dedicated to accelerating discovery and improving the rigor, transparency, and reproducibility of research. So it may be surprising that we are writing in opposition, as others have done, to a rule whose title would lead one to think its good for science. We oppose it because it wont do what it alleges to do: increase transparency or improve the health and safety of people or the environment.

Various stakeholders in science including researchers, funders, publishers, private organizations, and various public groups are constantly working to maintain and improve the integrity of scientific research. The proposed EPA rule may seem on the surface to support that goal. But it is instead a misguided proposal that undercuts the ongoing efforts of the scientific community in favor of dangerous vetting by a regulatory agency that will not have access to the best information.

Moreover, the Office of Management and Budget estimated that complying with the transparency rule would initially cost $250 million, and then between $1 million and $100 million a year, making it an expensive boondoggle that reduces the quality of information available to EPA policymakers.

Independent validation and replication of the research on which significant regulatory actions are based is a worthwhile goal. But that wouldnt happen under the EPAs rule. Research journals are increasingly implementing data availability policies that, unlike this rule, dont impose onerous burdens on researchers and EPA administrators and that respect the need to protect the privacy of human subjects when sensitive public health data are involved.

In an editorial in PLOS Medicine, Stanfords John Ioannidis writes, If the proposed rule is approved, science will be practically eliminated from all [EPA] decision-making processes. Regulation would then depend uniquely on opinion and whim. This would be devastating to the EPA and would harm Americans.

The EPA was established in the Nixon administration after the Love Canal environmental disaster, and was strengthened in the Reagan era. This supposedly non-partisan organization must rely on the best available research and minimal political interference to devise regulations that balance safety with vigorous commercial growth. When the EPA comes under political pressure, the consequences are severe, as when former EPA head Christie Whitman incorrectly testified about post-9/11 air quality in lower Manhattan. With the EPA responsible for regulations such as the Food Quality Protection Act, which in 1999 finally removed dangerous organophosphate pesticides from our food, political interference can cost lives.

The attention given lately to the challenges in repeating and extending results of research reported in individual published papers has given rise to new tools and practices to further strengthen the scientific endeavor. Over time, given the self-correcting nature of research, science uncovers the truth. While any single result may be difficult to reproduce, with evidence and consensus, novel claims are verified or refuted, and theories are confirmed or modified.

To be sure, there are countless ways to improve the research enterprise and to strengthen the rigor of individual research studies. Government agencies are in a position to play an effective role in encouraging these changes, but the EPAs proposed transparency rule does nothing of the sort.

Reducing the EPAs reliance on scientific knowledge will undermine science and have a catastrophic impact on the health of the country and its citizens.

Lenny Teytelman, Ph.D., is CEO of protocols.io in Berkeley, California. William Gunn, Ph.D., is director of scholarly communications at Elsevier. Joanne Kamens, Ph.D., is executive director of Addgene in Cambridge, Massachusetts.

View original post here:
EPA's 'transparency rule' is bad for science and the environment - STAT

Read More...

Myriads Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes – Yahoo Finance

December 15th, 2019 9:53 pm

New Clinical Validation Study Presented at 2019 San Antonio Breast Cancer Symposium

SALT LAKE CITY, Dec. 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced that results of a new validation study of the companys polygenic risk score (PRS) for breast cancer were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx. The key finding is that the PRS significantly improves the precision and accuracy of breast cancer risk estimates for women of European ancestry who have pathogenic variants (PV) in high- and moderate-penetrance breast cancer genes.

Our goal is to help women understand their risk of breast cancer so that they can take steps to live longer, healthier lives. Women who have a family history of breast cancer should consider hereditary cancer testing with the myRisk Hereditary Cancer test, said Jerry Lanchbury, Ph.D., chief scientific officer of Myriad Genetics. In this landmark study, we demonstrated that for women who test positive for a mutation in one of the five most common breast cancer genes, there are additional genetic factors called single nucleotide polymorphisms (SNPs) that can further influence their lifetime risk of breast cancer.

A summary of the study follows below. Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates by using the #SACBS19 hashtag.

Myriad Poster Presentation Title: Polygenic Breast Cancer Risk Modification in Carriers of High and Intermediate Risk Gene Mutations.Presenter: Elisha Hughes, Ph.D.Date: Saturday, Dec. 14, 2019, 7:009:00 a.m. Location: Poster P6-08-07

This validation study evaluated the 86-SNP PRS as a breast cancer risk factor for women who carry PV in the BRCA1, BRCA2, CHEK2, ATM and PALB2 genes and for PV-free women. The analysis included data from 152,012 women of European ancestry who received a myRisk Hereditary Cancer test as part of their clinical hereditary cancer risk assessment. The results demonstrated that the 86-SNP PRS significantly modified the breast cancer risk for women with pathogenic mutations in the five tested breast cancer genes (p-value <10-4). For some women, the PRS significantly increased the gene-based risk of breast cancer, while in others the gene-based risk was reduced (see Graph 1). Importantly, the greatest PRS risk-modification was observed in carriers of CHEK2, ATM and PALB2 mutations with some women reaching the risk levels associated with BRCA1 and BRCA2 mutations.

To viewGraph 1: PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers , please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/d56c93ca-e00f-452d-b051-6325a578454c

These findings mean that we have the potential to significantly improve the precision of hereditary cancer risk assessment for women who test positive for mutations in the high and intermediate risk breast cancer genes, said Elisha Hughes, Ph.D., lead investigator and director of Bioinformatics at Myriad Genetics. We are optimistic that this additional genetic information can help clinicians more accurately predict the risk of breast cancer and provide the best care for their patients in the future.

Next StepsThe company plans to publish these new data in a peer reviewed medical journal and make the PRS available for U.S. women of European ancestry who test positive for mutations in breast cancer genes. The PRS currently is available as part of myRisk Hereditary Cancer enhanced with riskScore for women of European ancestry who test negative for pathogenic mutations in the breast cancer genes. Specifically, the riskScore test combines the PRS with the Tyrer-Cuzick model to estimate a womans 5-year and lifetime risk for developing breast cancer. The company is committed to making myRisk Hereditary Cancer enhanced with riskScore available to all ethnicities and is developing the test for women of Hispanic and African-American ancestry who test negative. The company is currently conducting the largest ever PRS study in African Americans and will present the data at a future meeting.

Story continues

Please visit Myriad at booth #113 to learn more about our portfolio of genetic tests for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news by using the hashtag #SABCS19.

AboutriskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys polygenic risk score and data being featured at the 2019 San Antonio Breast Cancer Symposium being held Dec. 10-14, 2019 in San Antonio, Tx.; the potential to significantly improve the precision of hereditary cancer risk assessment for women who test positive for mutations in the high and intermediate risk breast cancer genes; this additional genetic information helping clinicians more accurately predict the risk of breast cancer and provide the best care for their patients in the future; publishing these new data in a peer reviewed medical journal and making the PRS available for U.S. women of European ancestry who test positive for mutations in breast cancer genes; making myRisk Hereditary Cancer enhanced with riskScore available to all ethnicities and developing the test for women of Hispanic and African-American ancestry who test negative; conducting the largest ever PRS study in African Americans and presenting the data at a future meeting; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Link:
Myriads Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes - Yahoo Finance

Read More...

Here’s why many CRISPR/Cas9 experiments could be wrong and how to fix them – Massive Science

December 15th, 2019 9:53 pm

Every living cell on Earth has proteins. Typically thousands of them, that serve as molecular machines to digest food, sense the environment, or anything else a cell must do. However, many genes, and the proteins they code for, have unknown functions. In humans, the function of about 1 out of 5 of genes is unknown. To explore these dark corners of the genome, scientists can break up DNA to disable a gene, making their encoded proteins nonfunctional, and watch what happens to cells as a result, inferring the lost function from what goes wrong.

When CRISPR/Cas9 came online in 2012, it offered scientists a tool to do exactly this cut genes. The Cas9 enzyme searches through DNA, using a "guide RNA" to look for a specific sequence, and makes a cut when it finds a match. The gene, split in two, is repaired by the cell, but often with a large chunk missing. Many scientists assume that if a chunk of a gene is missing then the protein that it encodes will not function, or even be produced.

Researchers at the European Molecular Biology Laboratory in Heidelberg, Germany used CRISPR to make cuts in 136 different genes. In about a third of cases, proteins were still produced from these "damaged" genes and, furthermore, many of the proteins remained partially functional. This strange phenomenon, of damaged DNA producing functional protein, does more than punctuate lifes remarkable adaptability and resilience.

It means that dozens, or hundreds, of studies that used CRISPR/Cas9 to knock out genes, but failed to validate that the encoded protein was fully removed, could be incorrect or misleading.

While many labs that use CRISPR to knock out genes dovalidate that the encoded protein is no longer produced, other labs fail to check. Searching for one protein in a cell is time-consuming and technically challenging; testing for protein function takes even longer. There are some methodsavailableto look for specific proteins, but many CRISPR/Cas9 studies fail to run these experiments or scientific journals dont ask for the data.

While many labs that use CRISPR to knock out genes do validate that the encoded protein is no longer produced, other labs fail to check.

Nature Methods, the same journal that published the paper from the Heidelberg laboratory, recognized shortcomings in CRISPR validation early on. In 2017, they highlighted agenome-editing consortium, in collaboration with theUS National Institute of Standards and Technology, that aims to develop standardized procedures for CRISPR research, including publishing guidelines that include which guide RNAs were tested, how they were designed, and which controls were used in experiments.

The problem with major scientific developments, especially CRISPR/Cas9, is that experimental tools often explode in popularity before scientists and editors can implement standard procedures. When DNA sequencing was developed in the 1970s, for instance, there was little need for standards because it was so challenging to decipher the sequence of even a short piece of DNA. A decade later, however, GenBank, a DNA sequence repository, came online and journals began to mandate that researchers deposit their sequences. This requirement, together with reporting standards issued by journals likeNature, have ensured that a rapidly growing collection of DNA sequences can be vetted and independently analyzed by the scientific community. The same is true for methods like x-ray crystallography, with journalsrequiring that protein structures be independently validated and uploaded to publicly-accessible databases.

But while some scientists were shocked by the new study, others took a laissez-faire approach to the findings. On Twitter, many vented their rage at what they felt was a lack of careful controls by the scientific community. Raphael Ferreira, a postdoctoral fellow at Harvard Medical School, was inspired, perceiving this study as a game changer for the CRISPR community.

I was surprised by the results in a really positive way, as this paper rings the wake-up call for every scientist using CRISPR/Cas9, Ferreira said.

Despite the enthusiasm, however, Ferreira will not change how he performs his own experiments. The few times I have [used CRISPR/Cas9] in mammalian cells, I have always confirmed them with a Western blot, referring to an experimental method to detect specific proteins.

Victor de Lorenzo, a research professor at the National Center for Biotechnology in Madrid, agreed, claiming that, the only way to ensure that a protein is altogether removed is by making a Western blot.

Down the hall or across the street from my office, dozens of scientists use CRISPR/Cas9 to uncover protein functions. One of these researchers is Shashank Gandhi, a PhD student at the California Institute of Technology (CalTech) that has published CRISPR/Cas9 methods to delete genes in chicken embryos. Though he agrees with Ferreira and de Lorenzo, Gandhi asserts that validations could be taken a step further, and believes that journal editors should take action.

I think that journal editors should encourage authors to present supplemental data on how the knockouts were validated, insists Gandhi. I know that Nature requires that information as part of a "research summary" document that is submitted to the journal with each paper submission.

CRISPR/Cas9 validations could be taken a step further, and this is where journal editors can take action.

If Nature, which is widely considered the premier academic research journal, takes action to ensure that CRISPR knockouts are validated, then perhaps other publishers will take notice. In the meantime, Gandhi and others are not taking any chances.

I use several approaches to validate my CRISPR knockouts. For starters, I design and test multiple [guide RNAs] targeting the same gene for all my knockout experiments. Secondly, wherever applicable, I try to perform rescue experiments to establish loss of function phenotypes, says Gandhi, referring to an experiment in which a deleted gene is restored to test whether that proteins phenotype returns, confirming a link between a gene and the function that was lost when the gene was broken.

While all of the scientists that I spoke with agreed that researchers could do more to double check their experiments, it is unclear what actionable steps could be taken. Perhaps a combination of scientific, academic, and institutional changes could alleviate the potential for misleading studies. Faster experimental methods to detect proteins, standardized publishing procedures, and an academic database that describes which guide RNAs have been tested in each organism, would all serve to enhance the rigor of current studies.

Unfortunately, academic institutions and scientific publishers are hulking bureaucracies with slow-moving policy changes. Ensuring that CRISPR/Cas9 produces repeatable experiments rather than blemishes on the scientific record will require the collective action of scientists. It will demand self-governance.

Excerpt from:
Here's why many CRISPR/Cas9 experiments could be wrong and how to fix them - Massive Science

Read More...

U. professors Conley and Tilghman recognized as AAAS Fellows – The Daily Princetonian

December 15th, 2019 9:53 pm

Professors Dalton Conley (left) and Shirley Tilghman (right), who were named AAAS fellows

Dalton Conley and Shirley Tilghman have been named 2019 fellows of the American Association for the Advancement of Science (AAAS) for their scholarship in the fields of sociology and molecular biology, respectively.

AAAS is a non-profit organization that seeks to promote scientific cooperation, integrity, education, and policy. Founded in 1848, it is now the worlds largest general scientific society with over 120,000 members. The association is also responsible for publishing the well-established journal Science.

AAAS Fellows, elected annually, are chosen based on their achievements in a variety of aspects of science. Sections include, but are not limited to, Chemistry, Agriculture, Food, and Renewable Resources, Anthropology, Education, History and Philosophy of Science, Linguistic and Language Sciences, and Biological Sciences. The position is honorific, inducting scholars into the community but not requiring active participation.

The fellowship is a lifetime honor. Last year, University professors Rebecca Burdine and Elke Weber were appointed to the position. 37 members of Princetons faculty currently hold AAAS fellowships.

Conley, the Henry Putnam University Professor of Sociology, is recognized by AAAS in the Section on Social, Economic, and Political Sciences. At the University, he is also a faculty affiliate at the Office of Population Research and the Center for Health and Wellbeing. He currently teaches a year-long class on how to conduct quantitative research studies to answer sociological questions, as well as a biosociology class. His research focuses on the intersection between genetics and social science.

What are the relative contributions of nature and nurture to who we become, and how do the biologically hardwired aspects of ourselves play out in the world and depend on the world? Conley stated as the broad questions that drive his research.

With degrees in both sociology and biology, Conley uses empirical studies which rely on naturally produced factors, or natural experiments, combined with new genomic tools to answer sociological questions. His recent work concerns genetic differences between siblings and their impact on social relationships within families.

Tilghman is the President of the University, Emeritus, and professor of molecular biology and public affairs. Her research focus is mammalian developmental biology and science policy. After serving as President from 20012013, she returned to the faculty and now advises juniors and seniors on independent work. The AAAS fellowship recognizes her distinguished contributions in molecular biology as well as her esteemed leadership of the University.

Probably the most exciting aspect of this is to be selected along with [Tilghman], who I and so many others at Princeton have so much admiration for for her research, teaching, and leadership, Conley said. That was the coolest part, to be grouped in with her.

Conley and Tilghman will be honored in Seattle on Feb. 15 during the AAAS annual meeting, and in the Nov. 28 issue of Science.

See more here:
U. professors Conley and Tilghman recognized as AAAS Fellows - The Daily Princetonian

Read More...

GCRC postdoc recognized nationally and globally – McGill Reporter

December 15th, 2019 9:53 pm

Elena Kuzmin

A postdoctoral fellow in the lab of Prof. Morag Park at the Goodman Cancer Research Centre (GCRC), Elena Kuzmins work has been garnering a fair amount of recognition recently. After having received a Banting Postdoctoral Fellowship from the Canadian Institutes of Health Research back in May, Kuzmin was selected to be a Fellow of the Global Future Council on Biotechnology, World Economic Forum.

Most recently, on November 25, she was honoured with the Women in Science Research Excellence Fellowship, LOral Canada with the support of the Canadian Commission for UNESCO.

It is an honour to be the recipient of these fellowships in recognition of my work, says Kuzmin. This funding enables me to build networks by supporting my attendance to national and international conferences, where I can present my research and discuss the findings with peers and leaders in the field. Most importantly, it has enabled me to receive an unmatched training opportunity at McGill, to make a significant contribution to our understanding of cancer biology and hopefully to establish a well-rounded research program of my own studying complex genetic interaction networks in yeast and human cells.

The LOral Canada fellowships are meant to enhance the role of women in devising scientific solutions to problems confronting humankind in the 21st century. The purpose of this program is to support major research projects undertaken by Canadian scientists at the post-doctoral level in Canada.

The Global Future Council on Biotechnology is the worlds foremost knowledge network dedicated to promoting innovative thinking on the future and aims to launch initiatives capable of accelerating new medical biotechnological discoveries, diagnostics and therapeutics. The council consists of 20-25 members, including industry leaders, government officials and academic researchers, such as postdoctoral fellowsand faculty members from around the world.

Elena is at the forefront of applying complex genetic approaches to understand breast cancer interaction and progression, notes Park, who is also the Director of the GCRC. She is a role model for young women in science.

Kuzmin completed her Honours BSc with High Distinction in Human Biology and Zoology and her MSc in the Department of Laboratory Medicine and Pathobiology at the SickKids Research Institute, University of Toronto. She then went on to do her PhD in the Department of Molecular Genetics at the University of Toronto with Profs. Charles Boone and Brenda Andrews, where she studied complex genetic interaction networks in the budding yeast.

In her current work, Kuzmin is applying the principles of complex genetic interactions to address a current challenge in human disease the onset and progression of triple negative breast cancer. This subset of breast cancer has no targeted therapies, since it lacks 3 common biomarkers such as estrogen and progesterone receptors and Her2, and has the worst survival rates. The aim of her project is to use single-cell genomic and transcriptomic sequencing technologies combined with genetic screens to gain insight into the evolution of large copy number variants, which are characteristic of this cancer type. Ultimately, this research is expected to reveal genetic events that modulate triple negative breast cancer, enhancing our understanding of the disease and offering possible avenues for personalized interventions to affected individuals.

Go here to see the original:
GCRC postdoc recognized nationally and globally - McGill Reporter

Read More...

UCLA’s university housing projects are unlikely to reduce rent rates in Westwood – Daily Bruin

December 15th, 2019 9:53 pm

Several university housing projects set to be completed in the next few years are unlikely to lower rent costs in Westwood, experts say.

Westwood Village has been rated the most expensive place to rent in California. The high cost of rent can be burdensome for students, especially those who must live off campus. At the same time, a growing percentage of students on the Hill are expected to live in triple-occupancy dorms.

UCLA Housing previously announced its goal to guarantee four years of university housing for first-year students and two years for transfer students as part of its 2016-2026 master plan, which states its primary goals for housing development over the next 10 years.

To reach this target, UCLA Housing has begun construction on three new projects expected to create over 5,000 beds for undergraduate and graduate students. However, experts said these projects will do little to reduce rent costs for private housing in Westwood.

The first of these housing projects is the Lot 15 Residence Hall, which will include two eight-level mid-rise structures that will provide on-campus housing for first- and second-year undergraduates, according to the UCLA Housing website.

The second housing project is the Southwest Campus Apartments, three 8-to-10 story buildings that will provide 321 graduate beds and 1,958 upper-division undergraduate beds. The last of these housing projects is the 10995 Le Conte Avenue Apartments, which will provide 1,167 beds for upper-division undergraduate students.

UCLA Housing & Hospitality Services said in a statement that the rates for its housing units are not determined by the private rental market. University housing rates are determined to ensure that UCLA Housing & Hospitality remains self-financing, meaning they aim to secure funding to maintain current buildings while also gathering enough funds for future projects.

The current rates for UCLA Housing units range from $7,715.52 per academic year for a hall-style dorm to $16,872 per academic year for a university apartment. These rates do not include meal plans or social fees.

Dana Cuff, an architecture, urban design and urban planning professor at UCLA, said she does not believe that the new housing projects will have any effect on rent in Westwood. Cuff, who is also the director of cityLAB UCLA, said this is because the demand for housing in Westwood is disproportionately higher than the supply, which creates pent-up demand. However, she added that these projects could slow down the increase in rent.

Theres such a housing crisis and such pent-up demand, particularly among students to live near campus, that as soon as these new apartments come, they will be snapped up. It is not likely to pressure rents downwards, she said. If I were to predict, Id say rent might not continue to go up at the same rate, it would slow down rent increases that would be a good result.

Michael Lens, an urban planning and public policy associate professor at UCLA, said the effect of these new housing projects will be minimal.

I think that the impact will be very, very small, and close to nothing on the private market, he said. You are trying to play catch to very slow construction activity over recent years and decades even in this part of town. It is not a very big change in supply, he added.

North Westwood Neighborhood Council President Michael Skiles said UCLA remains an attractive option for students because UCLA typically charges around 30% below the market rate for housing. He added that these new buildings could slow down the increase in rent prices, but said he was unsure if rent would decrease in Westwood.

They are either going to result in lower rent or at least slow the rate at which rents in Westwood increase, Skiles said. What remains to be seen is whether it will slow (the price) so much just to actually reverse (increasing rent) and bring costs down a bit, or if it will instead just stop it from increasing.

Skiles said this uncertainty is due to the fact that UCLA does not guarantee housing for fourth-year undergraduate students and has historically offered limited housing for graduate students.

When the students get kicked out of housing, they have to compete for very few spots in Westwood all of them competing for scarce housing drives up the cost, he said.

The record-high rent in Westwood has prompted growing concerns among some UCLA students.

Chew Tin Zar Aung, a third-year microbiology, immunology and molecular genetics student, shared her concerns about the financial burden that high rent places on UCLA students.

While Westwood is a high-income neighborhood, it is still mainly populated by college students, and if we fail to protect (against) the rise in prices, this could be troublesome for students, she said. From my experience, it seems as if the rent in Westwood is getting worse every year.

Arvind Swaminathan, a third-year materials engineering student, said the high rent can still be significant burden for students with enough financial aid to cover tuition.

I think many students are in agreement that rent is important to them, Swaminathan said. While a lot of students already receive financial aid from the school for things like tuition, some still have trouble finding ways to pay for things like housing.

Piyapan Chaiprasit, a third-year business economics student, said she did not feel satisfied with the lack of affordable housing options in Westwood.

I think the situation is getting worse in Westwood because landlords keep trying to increase rent prices every year. Housing management companies will try to take advantage of the high demand and keep raising their prices, knowing that students will have no choice but to pay for these prices this is very burdensome on the students who have to bear these financial costs, Chaiprasit said.

Read more here:
UCLA's university housing projects are unlikely to reduce rent rates in Westwood - Daily Bruin

Read More...

Effect of Aging on 28-Joint Disease Activity Score in Rheumatoid Arthritis – Rheumatology Advisor

December 15th, 2019 9:51 pm

Age-related increases in erythrocyte sedimentation rate(ESR) and 28-joint swollen joint count (28-SJC) scores without relevantcorresponding increases in patient global assessment (PGA) and 28-joint tenderjoint counts (28-TJCs) may imply that age-related processes such asphysiological ESR increase and soft tissue changes contribute to a higher28-joint Disease Activity Score (DAS28) in older patients, according to resultsfrom a concise report published inRheumatology.

The current study used the DAS28 and its components to investigate the potential effect of aging on patients with rheumatoid arthritis who are nave to treatment with disease activity in disease-modifying antirheumatic drugs (DMARDs) from the Norwegian Register of DMARDs. Investigators used linear regression to explore associations between age (<45, 45-65, and >65 years) and each component of the DAS28 while accounting for sex and education. They calculated adjusted predicted scores for each component and total scores for each age range. Because significant interactions were found between age and sex for the 28-TJC, PGA, and ESR (P<.001), researchers stratified regression models for sex. Education was a signicant covariate, leading investigators to calculate predicted scores across age categories for different levels of education. Disease duration was not included in the model because it proved to not be a significant confounder.

Baseline data were available for 2037 patients (mean age55.2 years; 68% women). Compared with the youngest age group, men older than 65years with an intermediate education level had a 25% higher 28-SJC and 56%higher ESR, and women with an intermediate education level had a 27% higher28-SJC and 51% higher ESR. The differences between 28-TJC and PGA werenegligible (men: 28-TJC 3% and PGA 1%; women: 28-TJC 1% and PGA 2%). Thedifference in total DAS28-ESR score between the youngest and oldest agecategory was 10% for both men and women. In absolute values, the DAS28 was 5.5in the oldest group compared with 5 in the youngest.

Study limitations included using baseline data from patientswho were DMARD-nave entering the Norwegian Register of DMARDs and thepotential for confounding variables; however, the study investigators concludedthat the present study indicates that age has a significant positiverelationship with the DAS28-ESR, with the ESR and 28-SJC driving the increase.Validation of disease activity measures in elderly RA patients should be performedin future studies where the influence of comorbidity and physiologicalageingis studied. The age effect on DAS28 might be relevant in atreat-to-target strategy, but longitudinal data are needed to further explorethis.

Reference van Onna M, Putrik P, Lie E, Kvien TK, Boonen A, Uhlig T.What do we measure with 28-joint DAS in elderly patients? An explorative analysis in the NOR-DMARD study[published online October 26, 2019].Rheumatology (Oxford). doi:10.1093/rheumatology/kez490

Follow this link:
Effect of Aging on 28-Joint Disease Activity Score in Rheumatoid Arthritis - Rheumatology Advisor

Read More...

Case Highlights Novel Approach to Treatment of UC, Psoriatic Arthritis – Monthly Prescribing Reference

December 15th, 2019 9:51 pm

A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.

The patient, a 52-year-old female with a long history ofpsoriatic arthritis, presented complaining of bloody diarrhea over the pastmonth. Stool studies and biopsies as well as a CT Scan of Abdomen and Pelvis wereperformed and revealed normal results. A colonoscopy, however, revealed thatthe patient had ulcerative colitis (UC) extending from the hepatic flexure torectum. Biopsies showed crypt abscesses consistent with inflammatory boweldisease (IBD) alone with a positive serum p-ANCA, the authors explained. Thepatient stated that she had no history of UC or IBD but did note that herpsoriatic arthritis had been unsuccessfully treated with Etanercept,Leflunomide, Adalimumab, and Methotrexate in the past.

The patients Secukinumab was discontinued and she wasinitiated on prednisone 40mg daily and mesalamine 4.8g daily. The patientimproved and was, therefore, discharged. To allow for a prednisone taper, shewas later initiated on Tofacitinib 10mg twice daily for treatment of bothpsoriatic arthritis and UC. In addition to complete resolution of her bloodydiarrhea, objective improvement of the patients psoriatic arthritis was alsoobserved.

In their discussion, the authors stated that, although therehave been case reports of Secukinumab-induced UC published in the past,treatment typically involves infliximab, a monoclonal TNF-alpha antibody, ifsteroids initially fail. For this patient, however, optimizing immunologic therapywas difficult since she was resistant to multiple forms of THF-alpha inhibitionwith Adalimumab and Etanercept. Because of this, a novel approach of initial steroidtherapy followed by treatment with Tofacitinib provided excellent resolution ofthe patients symptoms and conditions.

Nonetheless, psoriatic arthritis cases on Secukinumab who develop ulcerative colitis and have failed prior TNF-alpha antibody treatment merit this novel approach to therapy with Tofacitinib, the authors concluded. They added, We might consider Tofacitinib even in cases who have not failed prior TNF-alpha antibody treatment given greater acceptance by patients of oral medical therapy.

Reference

Sethi V, Jacobs A, Sethi A. Secukinumab induced ulcerative colitis in a patient with psoriatic arthritis: A novel approach to refractory cases. Presented at: 2019 AIBD Annual Meeting; December 12-14 in Orlando, FL.

See the rest here:
Case Highlights Novel Approach to Treatment of UC, Psoriatic Arthritis - Monthly Prescribing Reference

Read More...

Rare ‘telescoping fingers’ condition caused woman’s bones to reabsorb – ABC News

December 15th, 2019 9:51 pm

December 13, 2019, 6:46 PM

3 min read

Eerie X-rays portray a rare condition nicknamed "telescoping fingers," in which bone loss causes the fingers to buckle back into the hand, like a collapsing telescope.

A female patient, age 69, was diagnosed with rheumatoid arthritis 18 years prior and presented at a rheumatology clinic in Turkey with the condition, according to a case study published in the New England Journal of Medicine this week.

Her fingers could be stretched to their original length, but then retreated back into her hand when released. She could not completely flex her fingers, nor make a fist.

X-rays revealed that her bones had been reabsorbed as a late-state consequence of her severe arthritis.

A 69-year-old woman in Turkey developed a rare condition known as "telescoping fingers."

Doctors treated her with a series of arthritis drugs, which reduced her pain and swelling but did not improve her hand functionality.

While an estimated 23% of Americans have some form of doctor-diagnosed arthritis, according to the Centers for Disease Control and Prevention, developing telescoping fingers is extremely rare, even among people with arthritis.

The first case of the telescoping condition, described in the Journal of Bone and Joint Surgery, was documented in 1913, and referred to it as "la main en lorgnette," or opera-glass hand.

Read more:
Rare 'telescoping fingers' condition caused woman's bones to reabsorb - ABC News

Read More...

Teacher With Severe Arthritis Urges Others With Disabilities To Stay Active – The Chattanoogan

December 15th, 2019 9:51 pm

It may have been a rainy day, but the dreary weather did little to dampen Sharon Stolbergs enthusiasm when speaking about SPARC (Sport, Art, and Recreation of Chattanooga) to the Civitan Club.

The teacher at Hunter Middle School, who has suffered from a severe form of arthritis for her entire life, has devoted herself to helping children with disabilities. She does so by encouraging disabled students to participate in adaptive sports.

Adaptive sports, such as wheelchair basketball, use unique equipment to make those activities accessible to people with disabilities. Possessing the ability to play these sports has several benefits to children and adults, said the middle school teacher.

Adaptive sports really increase confidence, said Ms. Stolberg on the benefits of adaptive sports, Theyre a good bridge builder between the disabled and the non-disabled population, and they help with strength and weight control.

Ms. Stolberg has been a proponent of adaptive sports for almost 15 years. Although they did not exist when she was a child, nothing stopped her from enjoying them as an adult.

I started horseback riding in 2005 in Cleveland, and then I got into adaptive water skiing, and it sort of avalanched after that, said the speaker on how she got into adaptive sports.

Ever since she started with SPARC, which is focused on adaptive sports, she has seen it grow from small beginnings into a widely accepted organization. And with growth, it has made her job much easier.

I think the demand has grown, and the acceptance has grown, said Ms. Stolberg, The willingness of people to work and modify has grown too. Going from having to scrounge for volunteers, and now we have many more volunteers than we would have a few years ago. Its just more public now, and more of an accepted thing, which is huge.

While adaptive sports are a blessing for many children, they can be a pricey endeavor for families. Organizations such as the Civitan Club often provide the funds necessary to make the crucial equipment needed for adaptive sports.

With the kids in the area, the Civitan Clubs are really essential to get things like adaptive bikes for them, said Ms. Stolberg.

Read more:
Teacher With Severe Arthritis Urges Others With Disabilities To Stay Active - The Chattanoogan

Read More...

Flu Season Is the Scariest Time of the Year When You Have JA – Juvenile Arthritis News

December 15th, 2019 9:51 pm

Halloween has passed, but the scariest time of the year has just begun: cold and flu season. Winter can be unsettling when you have juvenile arthritis. Some medications used to treat JA can weaken the immune system, making it easier to catch any viruses going around. Getting sick can be hard on kids with JA; they might feel extra soreness, and it may take them longer to feel better than their peers. They may even need to put JA treatments on hold until they recover.

Its natural to feel anxious at this time of year. Its especially worrying because kids often spend hours together in tight quarters such as day care, locker rooms, and classrooms. But there are many precautions you can take to help prevent the spread of disease.

Youngsters with JA should get a flu vaccine, especially if theyre using immunosuppressants. The best line of defense is to have everyone in your house get a flu shot, to reduce the risk of someone getting sick and spreading germs.

Keep communal spaces in the house clean and wash shared blankets frequently. Remind your children to wash their hands after gym classes and sports practices. Older kids and teens should keep sanitizer sprays on hand for use on personal sports equipment.

Even when youre taking all the precautions possible, it can be hard to avoid worrying. The last thing you want is for your child to get sick. It can be tempting to want to put them in a bubble.

But try to have faith in the flu shot; its an excellent first line of defense. And other options, such as antiviral medication, can make the flu easier to cope with. While its not a cure, it can reduce flu symptoms by one day, which is nothing to sneeze at. If your child is showing signs of an infection, such as a fever, its important to call the doctor right away. The doctor may recommend using one of these medications as a precaution.

Have faith in your children to do their part to stay clean. Encourage them to wash their hands before eating and to keep their hands to themselves. Older kids and teens often understand that these precautions are necessary. Even little ones can come around to the idea when you incorporate it into a routine.

I think its important to note that though its easy to get sick, it might not happen. Its entirely possible to stay healthy. While some years I felt as if Id caught every cold going around, some flu seasons passed without a hitch. Youll never know how the season will go, so try to be as positive as possible. With the right precautions, your family might do just fine this cold and flu season.

***

Note: Juvenile Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Juvenile Arthritis News, or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to juvenile arthritis.

Elizabeth Medeiros is a young adult who has dealt with juvenile arthritis since she was a small child. However, her pain hasnt stopped her from working on a product design degree in Boston. Her passion is to create products that make life easier for the chronically ill, such as shoes and walking canes. When shes not in class, Elizabeth enjoys writing about how shes coped with arthritis at such a young age. You can find more of her writings at ArthritisGirl.Blogspot.com and on Instagram @GirlWithArthritis.

See the article here:
Flu Season Is the Scariest Time of the Year When You Have JA - Juvenile Arthritis News

Read More...

Alberta will force patients to switch from biologics to cheaper biosimilar medications – The Globe and Mail

December 15th, 2019 9:51 pm

'Were expanding the [biosimilars] initiative to make sure that our drug programs in Alberta are going to be sustainable,' Alberta Health Minister Tyler Shandro, seen here, said in an exclusive interview.

Jason Franson/The Canadian Press

Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known as biologics to cheaper near-copies of the medications, a move that will save the province hundreds of millions of dollars in the coming years.

The major policy change in favour of the less-expensive versions, called biosimilars, will take effect by next summer and is expected to save $227-million to $380-million over the next four years. Alberta will become the second province after British Columbia to stop covering some of the brand-name biologic drugs that have driven significant increases in prescription-drug spending across the country.

But the provincial government intends to go even further than B.C., including more drugs in the first phase of its plan and introducing a tiered framework that will limit drug choices for patients with rheumatoid arthritis and Crohns disease who are starting biologics for the first time.

Story continues below advertisement

Were expanding the [biosimilars] initiative to make sure that our drug programs in Alberta are going to be sustainable," Alberta Health Minister Tyler Shandro said in an exclusive interview. We committed in the last election that we would find efficiencies and make sure that we were investing those savings.

The government is working to rein in Albertas health-care spending more broadly, an effort that has already drawn the ire of health-care workers unions and the Alberta Medical Association.

The provinces initiative is likely to earn plaudits from those who see promoting the less-expensive medications as a sensible way to free up money for other health-care priorities.

However, some gastroenterologists and patient advocacy groups, including Crohns and Colitis Canada, have expressed concern that inflammatory bowel disease patients forced to switch wont do as well on the cheaper drugs.

Health Canada and drug regulators around the world say biosimilars are as safe and effective as the original drugs they mimic.

Biologics are complex medications produced from living organisms and injected or infused into patients. They have dramatically improved the health of people with debilitating diseases such as rheumatoid arthritis and Crohns disease chronic illnesses for which there used to be few good treatment options.

In Alberta, government spending on biologics skyrocketed to $238-million in 2018-19, up from just $21-million a decade earlier.

Story continues below advertisement

Four of the top five drugs in terms of public spending in Alberta are biologics. At the top of that list is Remicade, also known as infliximab, an intravenous infusion for rheumatoid arthritis, Crohns disease and ulcerative colitis, which cost the provincial government as much as $91.2-million last year more than any other single drug.

The list price for Remicade in Alberta is $962.68 a vial, while the biosimilar versions, Inflectra and Renflexis, sell for $525 and $493 a vial, respectively. (List prices dont reflect the confidential discount deals that are now commonplace in the global pharmaceutical industry, meaning the Alberta government could be paying less.)

Biosimilars are almost like generics: They are cheaper near-copies of original biologic drugs whose patents have expired. However, biologics, unlike simple chemical pills, cant be replicated perfectly from batch to batch, even within the same brand.

That complexity has allowed some opponents to argue that biosimilars arent as safe or effective as original biologics, especially for patients who are being asked to switch for financial instead of health reasons.

But the bulk of the international evidence mainly from Europe, where more than 40 approved biosimilars are available has shown no significant differences in safety or efficacy after switching.

Albertas plan will require existing patients on government-sponsored drug plans to switch to the biosimilar versions of Remicade and four other drugs: Enbrel, which treats rheumatoid arthritis; Lantus, a long-acting insulin for diabetics; and Neulasta and Neupogen, both of which boost white-cell counts for chemotherapy patients.

Story continues below advertisement

Existing users of a drug called Copaxone for multiple sclerosis will be switched to a complex generic at the same time. The government is including the drug in its initiative even though it is not technically a biologic.

The changes are expected to affect about 22,000 Albertans with diabetes, 2,000 with Crohns disease or ulcerative colitis, 1,400 with rheumatic diseases, 750 with multiple sclerosis, 450 with low white-blood cell counts and 35 with plaque psoriasis.

The changes, which kick in July 1, 2020, do not apply to patients with private insurance or patients who pay out of pocket for their prescription drugs.

Children and pregnant women will be exempt. Physicians who believe there is a medical reason why a patient should not switch will be allowed to apply to the province for an exemption.

For patients with Crohns disease, rheumatoid arthritis and related rheumatic diseases who are either starting biologics for the first time or switching away from a biologic that has stopped working, a new tiered framework means they will have to try cheaper biologic options first.

For example, Crohns patients new to biologics will first have to try one of the two Remicade biosimilars or another IV drug called Entyvio before they are allowed to access public coverage of Humira, an expensive treatment that patients can self-inject but for which biosimilar alternatives are not yet available in Canada.

Story continues below advertisement

Current Humira patients will be allowed to retain government coverage for the drug.

Read more:
Alberta will force patients to switch from biologics to cheaper biosimilar medications - The Globe and Mail

Read More...

Benefits of CBD and Arthritis in the Human Body – MMJ Reporter

December 15th, 2019 9:51 pm

Post Views: 364

The endocrine system is a collection of glands all over the body that is responsible for the secretion of hormones into the bloodstream. An endocrine disorder happens when this system is no longer able to function properly.

The endocrine system is composed of a set of glands responsible for the production of hormones that play a vital role in the regulation of body signals. These include appetite, sleep, weight, breathing, and even puberty. Almost every aspect of the body has something to do with hormones.

Diseases such as diabetes, Graves Disease, and Cushings Syndrome are all endocrine disorders. Each of them is a unique disease treated in different ways, but CBD and endocrine diseases have become tangled one as a remedy for the other in the recent past.

How endocrine system disorders occur

Endocrine disorders occur when one or more endocrine glands no longer functions properly. If even one gland starts to produce too much or too little of a particular hormone, chances of an endocrine disorder occurring go up. Such a disorder can either be generic, or due to tumors, nodules or lesions inhibit an endocrine glands normal functioning.

In diabetes, for example, the pancreas does not produce enough insulin; and in hypothyroidism, the thyroid gland doesnt produce enough thyroid hormone. Hyperthyroidism is the opposite of this.

All in all, most endocrine disorders dont have a specific cure and can last with the patient for years or even their whole lives. If left untreated, they can result in the poor quality of life, general body pain, loss of weight, total inability to move, work or function and death.

However, there exist medications and therapies that can be used to manage the symptoms they exhibit. One of the ways these symptoms can be suppressed and managed is through the use of CBD.

CBD and the endocrine system

According to recent studies, CBD has the potential to regulate the endocrine system and manage harmful symptoms exhibited by some endocrine disorders. One case that stands out, in particular, is when the disorder is caused by the presence of a tumor on endocrine glands. CBD and endocrine diseases caused by cancer cells can be inhibited and, possibly have an invasion of prostate tumors prohibited.

There is also some evidence available that suggests CBD has some degree of influence over the production of hormones in some glands in the body, including the thyroid gland. Keep in mind that research into the effect of CBD on the endocrine system is in very preliminary stages, however.

What we are sure of, though, is the effect CBD has when it comes to keeping the symptoms of certain endocrine disorders under control. The most common of these are insomnia and anxiety.

Of all the uses CBD has found in the modern age, the most well-documented is its ability to reduce feelings of anxiety. This is thought to be as a result of its ability to bind directly with CB1 receptors in the brain and affect the production of cortisol and serotonin.

Serotonin is a mood-regulating hormone, whose deficiency is usually manifested via feelings of anxiety and depression. A high level of cortisol also leads to feelings of stress and impending doom, as exhibited by people with anxiety.

Another well-known property of CBD is getting rid of insomnia. Sleep is yet another part of human life thought to be controlled, at least in part, by the endocannabinoid system. This is done via the circadian rhythm, which keeps wakefulness and sleepiness in check. In people with anxiety, this rhythm can be thrown off, making them unable to fall asleep.

On the other hand, another common symptom of endocrine disorders is unsatisfying sleep. REM sleep is the part of sleeping where, if experienced properly, a person feels well-rested. In people with certain endocrine disorders and anxiety, REM sleep may be lacking. A CBD dropper or CBD tincture right before bed is a good way to

More:
Benefits of CBD and Arthritis in the Human Body - MMJ Reporter

Read More...

Page 790«..1020..789790791792..800810..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick